Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues

• Approximately $114 million in preliminary fourth quarter SYFOVRE revenue as strong launch continues
• Approximately $24 million in preliminary fourth quarter EMPAVELI revenue  
  

WALTHAM, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced preliminary U.S. net product revenues of approximately $138 million for the fourth quarter and approximately $366 million for the full year 2023 for SYFOVRE (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration and for EMPAVELI (pegcetacoplan) for adults with paroxysmal nocturnal hemoglobinuria (PNH).

Strong SYFOVRE launch continues:

• Approximately $114 million and $275 million expected in preliminary U.S. net product revenues in the fourth quarter and full year 2023, respectively.ⁱ
• Approximately 62,000 doses (commercial and sample vials) distributed to physician practices in the fourth quarter; approximately 160,000 total doses have been distributed in 2023.
• Approximately 95% of treated GA patients are estimated to be using SYFOVRE.ⁱⁱ
  

Continued momentum with EMPAVELI:

• Approximately $24 million and $91 million expected in preliminary U.S. net product revenues in the fourth quarter and full year 2023, respectively.ⁱ
• High patient compliance rate of 97%.ⁱⁱⁱ
• More than 50% of existing patients and more than 90% of new patients now use the EMPAVELI Injector, an on-body device designed to streamline self-administration, since the October Injector approval.ⁱⁱⁱ
  

“SYFOVRE is the market-leading treatment for GA, with approximately 160,000 doses distributed since launch. More patients than ever are benefiting from SYFOVRE, including the increasing treatment effects over time and flexible dosing, and we look forward to building on the momentum this year,” said Cedric Francois, M.D., Ph.D., co-founder and chief executive officer, Apellis. “Additionally, the high compliance observed with EMPAVELI speaks to the important impact of this medicine on patients’ lives. In addition to advancing our pipeline, we believe the tremendous commercial progress made in the past year has positioned us for an even stronger 2024.”